Literature DB >> 23737084

Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation.

Ana Paula Dias Demasi1, Elizabeth Ferreira Martinez, Marcelo Henrique Napimoga, Leandro Lopes Freitas, Jose Vassallo, Adriana Silva Santos Duarte, Andresa Borges Soares, Ney Soares Araujo, Vera Cavalcanti Araujo.   

Abstract

B cell malignancies are classified according to the postulated differentiation stage of the originating cell. During differentiation, structural and molecular changes occur to support massive processing of immunoglobulin in the endoplasmic reticulum (ER) of plasma cells at the final stage. When overloaded, the ER generates unfolded proteins and hydrogen peroxide (H2O2), which may cause cell death. Peroxiredoxins (Prxs) I and IV belong to a family of proteins able to catalyze peroxide detoxification. Here, we investigated a potential association of these enzymes with immunoglobulin production in B cell neoplasms. Our results demonstrated that the expression of Prx IV was induced as cells became competent to synthesize immunoglobulin light chains, as observed by immunohistochemistry in tissue sections of B cell neoplasms and also by qPCR and Western blotting analyses in malignant B cell lines. Prx I was frequently highly expressed, indicating additional regulatory processes besides ER activity. Results obtained exclusively with myeloma cells have shown that expression of Prxs I and IV, both at mRNA and protein levels, was associated with light chain secretion quantified by ELISA. We suggest that Prxs I and IV may provide survival advantages for terminally differentiated neoplastic B cells by the elimination of H2O2 and, in the case of Prx IV, by the conversion of this toxic in a functional agent driving oxidative protein folding in the ER. In this sense, multiple myeloma and lymphomas demonstrated to synthesize immunoglobulin chains may benefit from strategic therapies targeting the adaptive pathway to ER stress, including inhibition of Prxs I and IV activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23737084     DOI: 10.1007/s00428-013-1433-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  23 in total

1.  Plasma cell differentiation requires the transcription factor XBP-1.

Authors:  A M Reimold; N N Iwakoshi; J Manis; P Vallabhajosyula; E Szomolanyi-Tsuda; E M Gravallese; D Friend; M J Grusby; F Alt; L H Glimcher
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

Review 2.  Lymphoid malignancies: the dark side of B-cell differentiation.

Authors:  A L Shaffer; Andreas Rosenwald; Louis M Staudt
Journal:  Nat Rev Immunol       Date:  2002-12       Impact factor: 53.106

3.  Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells.

Authors:  Miki Nakamura; Tomomi Gotoh; Yutaka Okuno; Hiro Tatetsu; Takashi Sonoki; Shima Uneda; Masataka Mori; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Leuk Lymphoma       Date:  2006-03

4.  Immunohistochemical detection of immunoglobulin light chain expression in B-cell non-Hodgkin lymphomas using formalin-fixed, paraffin-embedded tissues and a heat-induced epitope retrieval technique.

Authors:  Cristina E Marshall-Taylor; Richard W Cartun; Daniza Mandich; Joseph A DiGiuseppe
Journal:  Appl Immunohistochem Mol Morphol       Date:  2002-09

5.  Oxidative protein folding by an endoplasmic reticulum-localized peroxiredoxin.

Authors:  Ester Zito; Eduardo Pinho Melo; Yun Yang; Åsa Wahlander; Thomas A Neubert; David Ron
Journal:  Mol Cell       Date:  2010-12-10       Impact factor: 17.970

6.  Generating disulfides enzymatically: reaction products and electron acceptors of the endoplasmic reticulum thiol oxidase Ero1p.

Authors:  Einav Gross; Carolyn S Sevier; Nimrod Heldman; Elvira Vitu; Moran Bentzur; Chris A Kaiser; Colin Thorpe; Deborah Fass
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-03       Impact factor: 11.205

7.  Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications.

Authors:  Olga Balague; Ana Mozos; Daniel Martinez; Luis Hernandez; Lluis Colomo; Jose Luis Mate; Julie Teruya-Feldstein; Oscar Lin; Elias Campo; Armando Lopez-Guillermo; Antonio Martinez
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

Review 8.  Oxidative folding: cellular strategies for dealing with the resultant equimolar production of reactive oxygen species.

Authors:  Yuichiro Shimizu; Linda M Hendershot
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

9.  Repression of major histocompatibility complex IA expression by glucocorticoids: the glucocorticoid receptor inhibits the DNA binding of the X box DNA binding protein.

Authors:  A Celada; S McKercher; R A Maki
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

10.  The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.

Authors:  Daniel R Carrasco; Kumar Sukhdeo; Marina Protopopova; Raktim Sinha; Miriam Enos; Daniel E Carrasco; Mei Zheng; Mala Mani; Joel Henderson; Geraldine S Pinkus; Nikhil Munshi; James Horner; Elena V Ivanova; Alexei Protopopov; Kenneth C Anderson; Giovanni Tonon; Ronald A DePinho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

View more
  9 in total

1.  Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.

Authors:  Pekka Peroja; Kirsi-Maria Haapasaari; Susanna Mannisto; Ilkka Miinalainen; Petri Koivunen; Sirpa Leppä; Marja-Liisa Karjalainen-Lindsberg; Milla Elvi Linnea Kuusisto; Taina Turpeenniemi-Hujanen; Outi Kuittinen; Peeter Karihtala
Journal:  Virchows Arch       Date:  2016-03-16       Impact factor: 4.064

2.  Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.

Authors:  Lukas Janker; Rupert L Mayer; Andrea Bileck; Dominique Kreutz; Johanna C Mader; Kirsten Utpatel; Daniel Heudobler; Hermine Agis; Christopher Gerner; Astrid Slany
Journal:  Mol Cell Proteomics       Date:  2019-02-21       Impact factor: 5.911

Review 3.  Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma.

Authors:  Sinan Xiong; Wee-Joo Chng; Jianbiao Zhou
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

4.  Why high cholesterol levels help hematological malignancies: role of nuclear lipid microdomains.

Authors:  Michela Codini; Samuela Cataldi; Andrea Lazzarini; Anna Tasegian; Maria Rachele Ceccarini; Alessandro Floridi; Remo Lazzarini; Francesco Saverio Ambesi-Impiombato; Francesco Curcio; Tommaso Beccari; Elisabetta Albi
Journal:  Lipids Health Dis       Date:  2016-01-12       Impact factor: 3.876

5.  Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.

Authors:  Rui Wu; Marcel Nijland; Bea Rutgers; Rianne Veenstra; Myra Langendonk; Lotte E van der Meeren; Philip M Kluin; Guanwu Li; Arjan Diepstra; Jen-Fu Chiu; Anke van den Berg; Lydia Visser
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

Review 6.  PRDX4 and Its Roles in Various Cancers.

Authors:  Wenqiao Jia; Pengxiang Chen; Yufeng Cheng
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

7.  Identification of differentially expressed proteins from Leishmania amazonensis associated with the loss of virulence of the parasites.

Authors:  Rubens D M Magalhães; Mariana C Duarte; Eliciane C Mattos; Vivian T Martins; Paula S Lage; Miguel A Chávez-Fumagalli; Daniela P Lage; Daniel Menezes-Souza; Wiliam C B Régis; Maria J Manso Alves; Manuel Soto; Carlos A P Tavares; Ronaldo A P Nagen; Eduardo A F Coelho
Journal:  PLoS Negl Trop Dis       Date:  2014-04-03

8.  Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma.

Authors:  Anna Trzeciecka; Szymon Klossowski; Malgorzata Bajor; Radoslaw Zagozdzon; Pawel Gaj; Angelika Muchowicz; Agata Malinowska; Anna Czerwoniec; Joanna Barankiewicz; Antoni Domagala; Justyna Chlebowska; Monika Prochorec-Sobieszek; Magdalena Winiarska; Ryszard Ostaszewski; Iwonna Gwizdalska; Jakub Golab; Dominika Nowis; Malgorzata Firczuk
Journal:  Oncotarget       Date:  2016-01-12

9.  The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy.

Authors:  Nelli Roininen; Kirsi-Maria Haapasaari; Peeter Karihtala
Journal:  Oxid Med Cell Longev       Date:  2017-11-19       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.